Genvor’s AGM182 Antifungal Peptide Technology Validated in Peer-Reviewed Publication in PhytoFrontiers™

Rhea-AI Summary

Genvor (OTCQB: GNVR) announced peer-reviewed validation of its AI-designed antifungal peptide AGM182 in PhytoFrontiers, reporting greenhouse results showing 76–98% reduction in total aflatoxin contamination in transgenic corn expressing AGM182.

The publication, co-authored with USDA-ARS, cites no adverse plant growth effects, a proven mammalian safety profile, activity versus Aspergillus flavus and Fusarium species, and follows U.S. Patent No. 12,458,684 co-assigned with USDA-ARS.

Positive

• Greenhouse aflatoxin reduction of 76–98%
• U.S. patent issued: No. 12,458,684 for transgenic corn with AGM182
• Peer-reviewed validation in PhytoFrontiers with USDA-ARS collaboration
• Study reports no adverse plant growth or yield effects

Negative

• Results are from greenhouse trials, not reported large-scale field trials
• Commercial impact depends on future licensing and regulatory steps not yet disclosed

Greenhouse trial results published jointly with USDA-ARS demonstrate 76-98% reduction in aflatoxin contamination in transgenic corn expressing the BioCypher-designed peptide AGM182

Woodland, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, today announced the publication of peer-reviewed research validating its proprietary AGM182 antifungal peptide technology in PhytoFrontiers™, a journal of the American Phytopathological Society. The study, conducted in collaboration with the United States Department of Agriculture’s Agricultural Research Service (USDA-ARS), demonstrates that transgenic corn expressing AGM182 achieves significant pre-harvest resistance to Aspergillus flavus and aflatoxin contamination.

The publication, titled, “Transgenic Expression of Antimicrobial Synthetic Peptide AGM182 in Developing Corn Ears Confers Pre-Harvest Resistance In Planta to Aspergillus flavus and Aflatoxin Contamination,” reports greenhouse trial results showing:

• 76-98% reduction in total aflatoxin contamination in corn expressing the AGM182 antifungal peptide
• No adverse effects on plant growth or yield
• Proven mammalian safety profile with no observed toxicity
• Activity against Aspergillus flavus and Fusarium species, key contributors to yield loss and grain contamination

Aflatoxins are naturally occurring toxic and carcinogenic compounds produced by Aspergillus flavus that contaminate corn and other crops, posing significant risks to human and animal health. Economic losses from fungal diseases in corn are substantial, with total annual U.S. losses estimated between $3 billion and $5 billion. Aflatoxin contamination alone has potential annual market impacts ranging from approximately $52 million in lower-risk years to $1.68 billion in high-risk years.

The peer-reviewed publication follows Genvor’s November 2025 announcement that the USPTO issued U.S. Patent No. 12,458,684 for transgenic corn with antifungal peptide AGM182, co-assigned with the USDA. Together, the patent and publication provide both intellectual property protection and independent scientific validation of the technology’s commercial potential.

“Peer-reviewed validation in a respected scientific journal is a critical milestone for Genvor and our AGM182 program,” said Chad Pawlak, Chief Executive Officer of Genvor. “This publication confirms that our BioCypher™ Algorithm can design peptides that deliver meaningful, measurable results against some of agriculture’s most costly challenges. AGM182’s broad-spectrum activity against Fusarium species and other major pathogens demonstrates the wider commercial potential of our platform. With patent protection and published research now in place, we are well-positioned to advance licensing discussions with partners seeking proven biological solutions for aflatoxin resistance and broader pathogen mitigation.”

“This publication represents the culmination of years of collaborative research between our team and the USDA,” said Dr. Jesse Jaynes, Professor of Biochemistry at Tuskegee University and founding scientist behind Genvor’s core technologies. “Seeing AGM182 validated through rigorous peer review in PhytoFrontiers confirms that computationally designed peptides can provide durable, safe, and scalable solutions for pre-harvest crop protection. This is precisely the kind of translational impact we set out to achieve.”

The research was conducted at the USDA-ARS Food and Feed Safety Research Unit at the Southern Regional Research Center in New Orleans, Louisiana, in collaboration with scientists from Tuskegee University and Genvor. The study builds on Genvor’s over 7-year Cooperative Research and Development Agreement (CRADA) with the USDA-ARS, which focuses on developing corn varieties resistant to pre-harvest aflatoxin contamination.

About Genvor

Genvor, Inc. (OTCQB: GNVR) is a biotechnology company pioneering peptide-based solutions for crop protection and plant health. With a focus on sustainable agriculture, Genvor develops and commercializes biological actives that enhance crop performance, reduce chemical inputs, and support regenerative farming systems. Through its partnerships and technology platforms, Genvor is advancing a new era of natural, science-based crop protection. For more information, visit www.genvor.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. Forward-looking statements include, among others, statements regarding the potential benefits, outcomes, and commercial applications of Genvor’s peptide technologies and research collaborations. Actual results may differ materially from those expressed or implied. Factors that could cause such differences include, but are not limited to, research outcomes, regulatory developments, market conditions, and the ability to execute on strategic initiatives. Genvor undertakes no obligation to update or revise forward-looking statements, except as required by law.

Contacts:

Genvor, Inc.
Investor Relations & Media
Carly Scaduto
carly@carlyscadutoconsulting.com

FAQ

What did Genvor (GNVR) publish about AGM182 on February 11, 2026?

Genvor published peer-reviewed greenhouse results showing 76–98% reduction in aflatoxin in transgenic corn. According to the company, the study was in PhytoFrontiers and co-authored with USDA-ARS, reporting safety and activity against Aspergillus flavus and Fusarium.

Does the PhytoFrontiers paper confirm safety and yield effects for AGM182 (GNVR)?

Yes — the publication reports no adverse plant growth or yield effects and a mammalian safety profile. According to the company, study authors observed no toxicity and reported agronomic performance unchanged in the greenhouse trials.

What intellectual property protection does Genvor (GNVR) have for AGM182?

Genvor holds U.S. Patent No. 12,458,684 co-assigned with USDA-ARS for transgenic corn expressing AGM182. According to the company, the patent complements the peer-reviewed validation and supports licensing discussions.

How does AGM182 affect pathogens that cause aflatoxin and yield loss for GNVR investors?

AGM182 shows activity against Aspergillus flavus and Fusarium species, which contribute to aflatoxin and yield loss. According to the company, greenhouse data demonstrate reduced contamination and broader pathogen mitigation potential.

What are the near-term limitations of Genvor’s AGM182 findings for GNVR shareholders?

Near-term limitations include that results are from greenhouse trials and not large-scale field or regulatory approvals. According to the company, further development, licensing, and regulatory work remain before commercial deployment.